TOKYO -- U.S.-based Arch Venture Partners has launched a $3 billion venture capital fund specializing in medical technologies, one of the world's largest of its kind, with Japanese startups among its potential targets.
Biotechnology
American VC firm Arch launches $3bn biomedical fund with eye on Japan
Fund looks to help develop startups short on capital, co-founder says
Japan has promising biotech startups that often lack the support needed to bring their technology to market. (Photo courtesy of Chordia Therapeutics)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Biotechnology
